Clinical trial · Interventional
Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
A Phase I Study to Evaluate the Safety and Efficacy of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a phase I clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce our patented product IKC (Immune Killer Cells). The IKC will then infused back into the patient to treat the cancer. Each patient will receive a total of six infusions.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma by BCLC Stage | Hepatocellular Carcinoma by BCLC Stage | ONTOLOGY_EXACT | 0.98 |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| NSCLC Stage IIIB | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| NSCLC Stage IV | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immune Killer Cells (IKC) | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Late stage lung cancer and liver cancer
- description
- Immune Killer Cells (IKC)
- interventionNames
- Biological: Immune Killer Cells (IKC)
Primary outcomes (1)
- measure
- Incidence of Treatment-Emergent Adverse Events [Safety]
- timeFrame
- 5 months
- description
- Adverse Events (AE) and Serious Adverse Events (SAE) will be recorded and evaluated for their relationship to the treatment
Secondary outcomes (2)
- measure
- Response Evaluation Criteria in Solid Tumors (RECIST)
- timeFrame
- 4 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. subjects had voluntarily given written informed consent 2. subjects had CT scan on lung or liver tumors within the past 4 weeks of the screening visit 3. subjects who were histologically or pathologically confirmed with locally advanced or metastatic lung cancer or HCC 4. subjects who did not have valid therapy, ever failed with other therapy, or refused or were not appropriate for other therapies for lung cancer or HCC 5. subjects' ECOG performance status ≤ 2 6. subjects with life expectancy ≥ 3 months Exclusion Criteria: 1. subjects with medical history of gout 2. subjects who had participated other clinical trials within 4 weeks before the screening visit 3. subjects with positive result of HIV or HTLV test within 4 weeks before the screening visit 4. subjects with clinically significant diseases other than cancer 5. subjects with myocardial infraction, stroke, or congestive heart failure within 3 months before the screening visit 6. female subjects who were pregnant or lactating or women of child-bearing potential but unable to take adequate contraception 7. subjects with history of alcohol, drug or other substance abuse 8. subjects with disease of bacteremia
References
Publications (0)
Data not yet available